Can new drugs punch holes in can­cer's pro­tec­tive bar­ri­er? For Parthenon Ther­a­peu­tics, that's the $65M ques­tion

4 years ago
Financing
Startups

An­tios Ther­a­peu­tic­s' hep B can­di­date gets an­oth­er round of ap­plause from in­vestors, clos­ing out a $171M megaround

4 years ago
Financing

Phase­Bio claims pos­i­tive PhII in platelet in­hi­bi­tion re­ver­sal; Tri­al soft­ware firm re­brands af­ter hack, merg­er

4 years ago
News Briefing

Weeks in­to first ap­proval, Cara waves good­bye to found­ing CEO in fa­vor of board mem­ber

4 years ago
People

CRISPR Ther­a­peu­tics co-founder un­cloaks an off-the-shelf cell ther­a­py start­up with $87M and a lot of fan­fare

4 years ago
Financing
Startups

Flag­ship and the Cys­tic Fi­bro­sis Foun­da­tion team up on a nov­el re­search pact to chase down po­ten­tial cures

4 years ago
Deals

Sage changes pri­ma­ry end­point in key study months af­ter an­a­lysts fret about de­pres­sion drug's dura­bil­i­ty

4 years ago
R&D

Am­gen spot­lights pre­clin­i­cal 'mul­ti-specific­s' as an­a­lyst pre­dicts late-stage M&A

4 years ago
R&D

Bay­er backs a George Church spin­out try­ing to turn lab-in­vent­ed amino acids in­to a new class of pro­tein ther­a­pies

4 years ago
Financing
Startups

Dems forge lim­it­ed agree­ment on Medicare drug price ne­go­ti­a­tions

4 years ago
Pharma
FDA+

Covid-19 roundup: Eli Lil­ly with­draws mAbs from EMA re­view

4 years ago
Coronavirus

Go­ing af­ter Hunt­ing­ton's dis­ease again, ex-Te­va R&D chief gets some cash for Prile­ni­a's re­newed ef­forts

4 years ago
Financing

In­tro­duc­ing Mar­ket­ingRx and why phar­ma mar­ket­ing mat­ters. Pay at­ten­tion biotechs, it’s not just for Big Phar­ma ...

4 years ago
Pharma
Marketing

Q&A: Mod­er­na’s chief brand of­fi­cer on nav­i­gat­ing the Covid-19 spot­light and chart­ing the biotech brand’s fu­ture

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: J&J boosts health eq­ui­ty goals in 6-city chal­lenge; Al­ler­gan Aes­thet­ics kicks off breast can­cer ...

4 years ago
Pharma
Marketing

Lead­ing pro­teomics play­er gets a trio of new part­ners; GV tries to pre­vent cer­vi­cal can­cer

4 years ago
News Briefing

Pfiz­er re­veals de­lays across the board for its clin­i­cal gene ther­a­py pro­grams

4 years ago
Pharma

As an­ti-in­flam­ma­to­ry space heats up, Pfiz­er spins JAK, TYK2 drugs in­to new start­up

4 years ago
Deals

Clene's mid-stage ALS drug hits a brick wall, but can an 'ef­fi­ca­cy sig­nal' save the day?

4 years ago
R&D

Covid-19 roundup: Pfiz­er rais­es 2021 vac­cine sales fore­cast to $36B; Lil­ly lands $1.3B treat­ment deal with US ...

4 years ago
Coronavirus

Dems res­ur­rect a scaled back plan for Medicare drug price ne­go­ti­a­tions

4 years ago
R&D
Pharma

Fresh off Kite and BeiGene deals, Shore­line ups the ante with a hefty crossover. But the biotech in­sists it's in no ...

4 years ago
Financing

No­var­tis en­lists transat­lantic start­up to dis­cov­er new pro­tein de­graders in $1.3B+ deal

4 years ago
Deals

Cal­i­for­nia judge sides with drug­mak­ers in $50B opi­oid law­suit

4 years ago
Pharma
First page Previous page 619620621622623624625 Next page Last page
A service from the Financial Times